Please assess the completion status of the following clinical trial:

Trial Title: A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients 18 to 65 years of age, inclusive, at the time of informed consent.~* Subjects with both a diagnosis of MDD, and in a current major depressive episode, as defined by DSM-IV-TR criteria~* Subjects willing to discontinue all prohibited psychotropic medications to meet protocol-required washouts prior to and during the trial period.~Exclusion Criteria:~* Females who are breast-feeding and/or who have a positive pregnancy test result during screening prior to receiving trial medication~* Subject has a current Axis I (DSM-IV-TR) diagnosis of: dementia, Schizophrenia, Bipolar, Eating disorder , Obsessive-compulsive disorder, Panic disorder, Posttraumatic stress disorder~* Subjects experiencing hallucinations, delusions or any psychotic symptomatology in the current major depressive episode.~* Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days~* Subjects currently treated with insulin for diabetes.~* Subjects with uncontrolled hypertension~* Subjects with known ischemic heart disease or history of myocardial infarction, congestive heart failure, angioplasty, stenting, or coronary artery bypass Surgery~* Subjects with a positive drug screen for cocaine, marijuana, or other illicit drugs~* Inability to swallow tablets or tolerate oral medication~* Abnormal laboratory test results, vital signs and ECG results~* Subjects who previously participated in any prior brexpiprazole clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo + ADT (Type: PLACEBO_COMPARATOR): Matching Placebo and assigned ADT
- Brexpiprazole + ADT (Type: EXPERIMENTAL): Brexpiprazole, flexible dose and assigned ADT
- Seroquel XR + ADT (Type: ACTIVE_COMPARATOR): Seroquel XR, flexible dose and assigned ADT

Based on this trial design, predict the completion outcome and termination type (if applicable).